Journal: Assay and drug development technologies
Article Title: A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug.
doi: 10.1089/adt.2020.1024
Figure Lengend Snippet: Fig. 2. BCMA CD3 bispecific antibody interferes extensively with measurement of total sBCMA by LBA. Four concentrations of BCMA CD3 bispecific antibody (blue squares =no spike, red triangle = 0.069 nM, inverted green triangle = 0.55 nM, purple diamond =6.9 nM, orange circle = 55 nM) were spiked into: (A) QCs prepared by spiking recombinant monkey sBCMA into surrogate matrix at 75.2, 8.84, 1.04, 0.12 nM (denoted HQC, MQC, LQC, and LLOQ, respectively) and (B) four naive cynomolgus monkey plasma samples with endogenous sBCMA. As the drug concentrations increased, the re- covered amount of sBCMA rapidly decreased. HQC, high quality control; LBA, ligand binding assay; LLOQ, lower limit of quantitation; LQC, low quality control; MQC, mid quality control.
Article Snippet: Polyclonal goat anti-human BCMA antibody (R&D Systems) and polyclonal rabbit anti-peptide (CSSTPPLTCQR) antibodies (Cambridge Research Biochemicals) were buffer exchanged into phosphate-buffered saline (PBS), pH 7.4 (Gibco, Grand Island, NY) using a Zeba spin desalting column, 40 k MWCO (Thermo Scientific) following the manufacturer’s instructions.
Techniques: Recombinant, Clinical Proteomics, Control, Ligand Binding Assay, Quantitation Assay